



**SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY**

I Background Information:

A 510(k) Number

K192175

B Applicant

ACON Laboratories, Inc.

C Proprietary and Established Names

On Call Express II Blood Glucose Monitoring System

D Regulatory Information

Product Code(s)	Classification	Regulation Section	Panel
NBW	Class II	21 CFR 862.1345 - Glucose Test System	CH - Clinical Chemistry

II Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable.

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. On Call Express Blood Glucose Monitoring System (k132086)
2. Submitter's statement that the **INDICATIONS FOR USE/INTENDED USE** of the modified device as described in its labeling **HAS NOT CHANGED** along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).

A description of the device **MODIFICATION(S)**, including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the **FUNDAMENTAL SCIENTIFIC TECHNOLOGY** of the modified device **has not changed. This change was for:**

- The claimed hematocrit range has expanded from 30-55% to 25-60%.
 - The meter housing material surface texture and color changed from smooth coating to textured and from black to white, respectively.
 - The meter size has decreased from 85 mm x 49 mm x 16.4 mm to 81.5 mm x 48.3 mm x 16 mm and the meter weight has changed from 50 g to 47.4 g (with batteries).
 - The meter has an increased memory from 300 records to 500 records with time and date.
 - The number of batteries has changed from 1 CR20323.OV coin cell battery to 2 CR20323.OV batteries.
 - Change in name from On Call® Express Blood Glucose Monitoring System to the On Call Express II Blood Glucose Monitoring System.
3. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.
 4. A Design Control Activities Summary which includes:
 - a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.
 - b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.

The On Call Express II Blood Glucose Monitoring System is intended for single-patient home use only. Disinfection efficacy studies were performed on the materials comprising the meter by an outside commercial testing laboratory demonstrating complete inactivation of viral hepatitis B virus (HBV) with the chosen disinfectant, DisCide Ultra Disinfecting Towelettes (EPA Reg. No: 10492-4). Robustness studies were also performed by the sponsor demonstrating that there was no change in performance or external materials of the meter after 260 cleaning and disinfection cycles designed to simulate 5 years of single-patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.